Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)
China · Delayed Price · Currency is CNY | Market Cap | 61.94B -0.1% |
| Revenue (ttm) | 39.55B -5.0% |
| Net Income | 3.28B +55.3% |
| EPS | 1.24 +57.6% |
| Shares Out | 2.64B |
| PE Ratio | 20.41 |
| Forward PE | 34.14 |
| Dividend | 0.32 (1.24%) |
| Ex-Dividend Date | Aug 4, 2025 |
| Volume | 5,530,530 |
| Average Volume | 14,165,529 |
| Open | 25.29 |
| Previous Close | 25.26 |
| Day's Range | 25.09 - 25.54 |
| 52-Week Range | 22.88 - 33.10 |
| Beta | 0.69 |
| RSI | 37.11 |
| Earnings Date | Mar 24, 2026 |
About SHA:600196
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetology respiratory... [Read more]
Financial Performance
In 2024, SHA:600196's revenue was 41.07 billion, a decrease of -0.80% compared to the previous year's 41.40 billion. Earnings were 2.77 billion, an increase of 16.13%.
Financial StatementsNews
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech
Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment
China's health-care sector may be next to face regulatory crackdown, says economist
Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...
Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations
Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.